DEVELOPMENT AND VALIDATION OF Q-ABSORBANCE RATIO SPECTROPHOTO-METRIC METHOD FOR SIMULTANEOUS ESTIMATION OF MANGIFERIN AND BERBERIN HCl IN BULK AND SYNTHETIC MIXTURE
HTML Full TextMETRIC METHOD FOR SIMULTANEOUS ESTIMATION OF MANGIFERIN AND BERBERIN HCl IN BULK AND SYNTHETIC MIXTURE
Harish Padh, Shraddha Parmar * and Bhavna Patel
Department of Pharmaceutical Sciences, Sardar Patel University, Vallabh Vidyanagar - 388120, Gujarat, India.
ABSTRACT: There are so many promising plant based chemical constituents are present which act as alternative therapy for the control of diabetes. But due to lack of its proper quality control parameters they are not widely used. The US FDA patent is approved for fixed dosage combination of Mangiferin (MF) and Berberin HCl (BER) as antidiabetic herbal formulation. Absorbance ratio method uses the ratio of absorbances at two selected wavelengths, one which is an iso-absorptive point and other being the λmax of one of the two components. From the overlay spectra of two phytomarkers, it is evident that MF and BER show an iso-absorptive point at 317 nm. The second wavelength used is 257 nm, which is the λmax of MF. The drug response with respect to absorbance was linear over the concentration range 5 - 30 μg/ml for MF and 10 - 60 μg/ml for BER. The percentage recovery of MF and BER as found to be 100.00% and 100.07% respectively. The method can be successfully employed for the simultaneous determination of MF and BER in pharmaceutical formulations. The developed method is validated as per ICH guideline Q2 (R1).
Keywords: |
Mangiferin, Berberin HCl, Simultaneous equation method, ICH guidelines, Quality control
INTRODUCTION: The number of drugs and drug formulations introduced into the market has been increasing at an alarming rate. These drugs or formulations may be either new entities or partial structural modification of the existing ones or novel dosage forms. The US FDA US 7867979 B2 patent is approved for fixed dosage combination of MF and BER as antidiabetic herbal formulation 1 - 2. The literature review suggested that various HPLC, HPTLC and UV-visible Spectrophotometric methods have been reported for estimation of MF and BER individually or in combination with other drugs from pharmaceutical dosage form.
It is also revealed that no UV spectroscopic method has been reported in the literature review for the combination formulation of Mangiferin and Berberin HCl. The condition thus, provides the scope of development of accurate, sensitive, reproducible and simple Spectroscopic method capable of estimating both the drugs from the formulation simultaneously 3, 4, 5, 6, 7, 8, 9.
EXPERIMENTAL:
Apparatus and Instrument: A double beam UV-Visible spectrophotometer (Shimadzu, model pharmaspec 1800) having two matched quartz cells with 1 cm light path and Electronic analytical balance, (Shimadzu AUX-220) was used. Corning volumetric flasks, pipettes of borosilicate glasses were used in the study.
Spectrophotometric Conditions:
1. Mode: Spectrum
2. Scan speed: Fast
3. Wavelength range: 400 - 200 nm
4. Absorbance scale: 0.00A - 2.00A
5. Initial base line correction: Methanol
Chemicals and Reagents: MF reference standard was purchased from Sigma Aldrich. BER reference standard was given as gift sample by Enovate life Mumbai.
Preparation of Standard Solutions: To Prepare standard solution of MF (100 μg/ml) and BER (1000 μg/ml), accurately weigh 25 mg of each drugs were transferred in two different 100 and 10 ml volumetric flasks respectively, dissolve and diluted up to mark with methanol, from these stock solutions, 5 ml and 1 ml aliquots of MF and BER respectively were transferred in two different 10 ml volumetric flasks and were diluted up to mark with methanol to get working standard solution having concentration of MF of 50 μg/ml and BER of 100 μg/ml.
Methodology: Absorbance ratio method uses the ratio of absorbances at two selected wavelengths, one which is an iso-absorptive point and other being the λmax of one of the two components. From the overlay spectra of two drugs, it is evident that MF and BER show an iso-absorptive point at 317 nm. The second wavelength used is 257 nm, which is the λmax of MF. Working standards were prepared in methanol and the absorbances at 317 nm (iso-absorptive point) and 257 nm (λmax of MF) were measured and absorptivity coefficients were calculated using calibration curve. The concentration of two drugs in the mixture can be calculated using following equations.
CX = [(QM – QY) / (QX -QY)] × A1 / ax1 .... (1)
CY = [(QM – QX) / (QY -QX)] × A1 /ay1 … (2)
Where, A1 and A2 are absorbances of mixture at 257 nm and 317 nm; ax1 and ay1 are absorptivities of MF and BER at 257 nm; ax2 and ay2 are absorptivities of MF and BER respectively at 317 nm;
QM = A2 / A1, QX = ax2 / ax1, QY = ay2 / ay1
Calibration Curve for MF and BER: To check linearity of the method, working standard solution having concentration in range of 5 - 30 μg/ml of MF and 10 - 60 μg/ml of BER were prepared from the standard stock solutions of both drugs. The absorbance was measured at 257 nm (λmax of MF) and at 317 nm (λmax of BER). Calibration curves were constructed by plotting absorbance vs. concentration.
Preparation of Sample Solution from Laboratory Prepared Synthetic Mixture: Synthetic mixture of MF (25 mg) and BER (75 mg) was prepared by using common excipients like corn starch (50 mg), Lactose (113 mg) and magnesium stearate (2 mg) per tablet. Tablet powder was prepared by calculating formula for 10 Tablets having label claim for MF and BER 25 mg and 75 mg respectively. From this mixture, powder equivalent to 45 mg BER was dissolved in 250 ml methanol and then sonicated for 15 min. and filtered through Whatman filter paper. From this solution, 2.5 ml aliquot was taken in 10 ml volumetric flask and diluted up to the mark with methanol to make final concentration of MF and BER, 15 μg/ml and 45 μg/ml, respectively which was used for assay.
RESULTS AND DISCUSSION:
Method Development: For this measurement, the solutions of MF and BER were prepared separately in methanol at a concentration of 15 μg/ml and 45 μg/ml respectively. They were scanned in the wavelength range of 200 - 400 nm. From the overlay spectra of two drugs, it is evident that MF and BER show an iso-absorptive point at 317 nm. MF showed 241 nm, 257 nm, 317 nm, 366 nm λmax from which 257 nm was selected as λmax of MF in this method due to good linearity Fig. 1.
Validation of the Proposed Method:
Linearity: Linear correlation was obtained between absorbance vs. concentration of MF and BER in the concentration ranges of 5 - 30 μg/ml and 10 - 60 μg/ml respectively and is shown in overlain chromatogram of MF and BER, Fig. 2 and 3 respectively.
Calibration curve data of MF and BER shown in Table 1 and 2. Regression parameters are mentioned in Table 3 and the linearity spectra and calibration curves of these two drugs at 257 nm and 317 nm are shown in Fig. 3, 4 and 5, 6 respectively.
FIG. 1: ZERO ORDER OVERLAIN SPECTRA OF MF (10 μg/ml), BER (45 μg/ml) AND COMBINATION (10 μg/ml MF AND 45 μg/ml BER)
FIG. 2: (A) OVERLAIN SPECTRA OF MF (5 - 30 μg/ml) IN METHANOL (B) OVERLAIN SPECTRA OF BER (10 - 60 μg/ml) IN METHANOL
Table 1: Linearity data for MF
S. no. | Concentration of MF
(μg/ml) |
At Wavelength 257 nm | At Wavelength 317 nm | ||
Absorbance (Mean ± SD) | % RSD | Absorbance (Mean ± SD) | % RSD | ||
1 | 5 | 0.224 ± 0.004 | 1.61 | 0.221 ± 0.003 | 0.44 |
2 | 10 | 0.391 ± 0.002 | 0.62 | 0.293 ± 0.004 | 0.94 |
3 | 15 | 0.555 ± 0.002 | 0.59 | 0.345 ± 0.004 | 0.34 |
4 | 20 | 0.687 ± 0.003 | 0.26 | 0.434 ± 0.002 | 0.55 |
5 | 25 | 0.745 ± 0.004 | 0.36 | 0.500 ± 0.002 | 0.72 |
6 | 30 | 0.895 ± 0.003 | 0.34 | 0.586 ± 0.004 | 0.94 |
Table 2: Linearity data for BER
S. no. | Concentration of BER
(μg/ml) |
At Wavelength 257 nm | At Wavelength 317 nm | ||
Absorbance (Mean ± SD) | % RSD | Absorbance (Mean ± SD) | % RSD | ||
1 | 10 | 0.305 ± 0.002 | 1.00 | 0.221 ± 0.005 | 1.05 |
2 | 20 | 0.415 ± 0.004 | 0.33 | 0.290 ± 0.004 | 1.01 |
3 | 30 | 0.525 ± 0.003 | 1.22 | 0.355 ± 0.004 | 0.75 |
4 | 40 | 0.637 ± 0.002 | 0.26 | 0.430 ± 0.002 | 0.45 |
5 | 50 | 0.745 ± 0.003 | 1.36 | 0.500 ± 0.005 | 0.71 |
6 | 60 | 0.860 ± 0.002 | 0.94 | 0.590 ± 0.005 | 1.40 |
TABLE 3: LINEARITY DATA
Parameter | MF at 257 nm | MF at 317 nm | BER at 257 nm | BER at 317 nm |
Linearity range (μg/ml) | 5 - 30 | 5 - 30 | 10 - 60 | 10 - 60 |
Regression equation | y = 0.0252x + 0.1487 | y = 0.014x + 0.142 | y = 0.0111x + 0.1931 | y = 0.007x + 0.141 |
Correlation coefficient (r2) | 0.9991 | 0.9980 | 1.000 | 0.9980 |
y-intercept | 0.1487 | 0.142 | 0.1931 | 0.141 |
Standard deviation of slope | 0.0056 | 0.0098 | 0.0054 | 0.0066 |
Accuracy: Accuracy of the method was confirmed by recovery study from marketed formulation at three levels of standard additions (80%, 100% and 120%). Percentage recovery for MF was in the range of 99.99 - 100.07%, while for BER, it was found to be in range of 99.84 - 101.10%. The results are shown in Table 4 and 5. Recovery greater than 98% with low SD justifies the accuracy of the method.
FIG. 3: CALIBRATION CURVE OF MF (5 - 30 μg/ml) AT 257 nm
FIG. 4: CALIBRATION CURVE OF MF (5 - 30 μg/ml) AT 317 nm
FIG. 5: CALIBRATION CURVE OF BER (10 - 60 μg/ml) AT 257nm
FIG. 6: CALIBRATION CURVE OF BER (10 - 60 μg/ml) AT 257nm
TABLE 4: RECOVERY DATA FOR MF
% Level | Conc. of MF in sample
(μg/ml) |
Conc. of MF recovered
(μg/ml) |
% Recovery of MF (% Recovery ± SD) | % RSD
|
80% | 12 | 11.90 | 99.99 ± 1.92 | 1.92 |
12 | 11.67 | |||
12 | 12.10 | |||
100% | 15 | 14.02 | 100.00 ± 0.65 | 0.65 |
15 | 15.98 | |||
15 | 15.10 | |||
120% | 18 | 18.09 | 100.07 ± 0.49 | 0.49 |
18 | 18.00 | |||
18 | 17.95 |
TABLE 5: RECOVERY DATA FOR BER
% Level | Conc. of BER in sample
(μg/ml) |
Conc. of BER recovered
(μg/ml) |
% Recovery of BER (%) | %
RSD |
80% | 36 | 36.11 | 101.83 ± 1.19 | 1.18 |
36 | 36.79 | |||
36 | 36.00 | |||
100% | 45 | 45.02 | 100.07 ± 0.14 | 1.12 |
45 | 44.98 | |||
45 | 45.10 | |||
120% | 54 | 54.09 | 99.84 ± 0.30 | 0.30 |
54 | 53.77 | |||
54 | 53.88 |
Precision:
Repeatability (n = 6): The repeatability was checked by scanning and measurement of the responses of solutions of MF (5 - 30 μg/ml) and BER (10 - 60 μg/ml) without changing the parameters of the proposed method. The procedure was repeated six times and % RSD was calculated. The data for repeatability for combined solution of MF and BER is presented in Table 6. % R.S.D was found to be 1.12% and 1.02% at 257 nm and 317 nm, respectively for MF and 1.03 and 0.90% at 257 nm and 317 nm respectively for BER. % R.S.D was less than 2% complied with the standard limits.
TABLE 6: REPEATABILITY DATA FOR MF AND BER
Drug | Conc. (μg/ml) | Abs. (Mean ± SD) at 257 nm | % RSD
|
Abs. (Mean ± SD) at 317 nm | % RSD |
MF | 15 | 0.555 ± 0.008 | 1.12 | 0.343 ± 0.006 | 1.02 |
BER | 45 | 0.759 ± 0.007 | 1.03 | 0.353 ± 0.004 | 0.90 |
Intra Day and Inter Day Precision (n = 3): The data for intraday precision for MF and BER is shown in Table 7. The % R.S.D. for Intraday precision was found to be 0.22 - 0.40% for MF and 0.34 - 0.56% for BER at 257 nm respectively and 0.45 - 1.26% for MF and 0.37 - 0.59% for BER at 317 nm respectively. The data for intraday precision for MF and BER is shown in Table 8. The % R.S.D. for interday precision was found to be 0.96 - 1.75% for MF and 1.58 - 1.89% for BER at 257 nm respectively and 0.96 - 1.01% for MF and 0.89 - 1.89% for BER at 317 nm respectively.
LOD and LOQ: The LOD was calculated by standard deviation of response and was found to be 2.33 μg/ml and 5.22 μg/ml for MF and BER respectively at 257nm, be 2.30 μg/ml and 4.32 μg/ml for MF and BER respectively at 317 nm. The LOQ was calculated by standard deviation of response and was found to be 3.91 μg/ml and 6.69 μg/ml for MF and BER respectively at 257 nm, be 3.22 μg/ml and 7.22 μg/ml for MF and BER respectively at 317 nm.
TABLE 7: INTRADAY PRECISION DATA FOR MF AND BER
S. no. | Drug | Concentration
(μg/ml) |
Absorbance
(Mean ± SD) at 257 nm |
% RSD
|
Absorbance
(Mean ± SD) 317 nm |
% RSD |
1 | MF | 10 | 0.391 ± 0.002 | 0.22 | 0.520 ± 0.005 | 0.45 |
2 | 15 | 0.555 ± 0.002 | 0.23 | 0.630 ± 0.005 | 0.67 | |
3 | 20 | 0.687 ± 0.003 | 0.40 | 0.756 ± 0.008 | 1.26 | |
1 | BER | 30 | 0.565 ± 0.004 | 0.44 | 0.522 ± 0.002 | 0.37 |
2 | 40 | 0.672 ± 0.003 | 0.34 | 0.635 ± 0.005 | 0.59 | |
3 | 50 | 0.745 ± 0.004 | 0.56 | 0.743 ± 0.005 | 0.54 |
TABLE 8: INTERDAY PRECISION DATA FOR MF AND BER
S. no. | Drug | Concentration (μg/ml) | Absorbance
(Mean ± SD) at 257 nm |
% RSD | Absorbance
(Mean ± SD) at 317 nm |
% RSD |
1 | MF | 5 | 0.391 ± 0.005 | 1.75 | 0.521 ± 0.006 | 1.00 |
2 | 10 | 0.545 ± 0.007 | 1.02 | 0.631 ± 0.003 | 1.01 | |
3 | 15 | 0.685 ± 0.008 | 0.96 | 0.755 ± 0.008 | 0.96 | |
1 | BER | 30 | 0.563 ± 0.008 | 1.58 | 0.523 ± 0.008 | 0.89 |
2 | 40 | 0.672 ± 0.007 | 1.65 | 0.636 ± 0.007 | 1.36 | |
3 | 50 | 0.744 ± 0.005 | 1.89 | 0.742 ± 0.007 | 1.85 |
Analysis of Synthetic Mixture: Here, 15 μg/ml solution of MF and 45 μg/ml solution of BER synthetic mixture were prepared in triplicate manner and analyzed. The assay was carried out as per regression equation. The result of assay is shown in Table 9.
TABLE 9: ASSAY OF SYNTHETIC MIXTURE
Drug | Amount of drug
(mg) |
% Amount found
(Mean % ± SD) |
MF | 25 | 100.83 ± 1.22 |
BER | 75 | 99.88 ± 0.70 |
CONCLUSION: A new, simple, accurate, and precise UV spectroscopic method was developed for the simultaneous estimation of MF and BER in bulk drugs and in the presence of tablet excipients. The recovery studies suggested non-interference of formulation excipients in the estimation. Hence, the proposed method can be used for the quality control of the cited drugs and can be extended for routine analysis of the drugs in their pharmaceutical dosage forms.
ACKNOWLEDGEMENT: The authors wish to thank Enovate life Mumbai and PRS Herbal Haryana for providing Berberine HCl as gift sample. We would like to acknowledge Sardar Patel University, Vallabh Vidyanagar for providing seed grant to support this research work.
CONFLICT OF INTEREST: Nil
REFERENCES:
- Chawla R et al.: Evidence based herbal drug standardization approach in coping with challenges of holistic management of diabetes: a Dreadful lifestyle disorder of 21st century, JDMD 2013; 12: 35.
- Guang’ai Xu: Drug composition for treating 2 type diabetes and diabetic chronicity complications, US 7867979 B2 2011.
- Jyotshna et al.: Uni-dimensional double development HPTLC densitometry method for simultaneous analysis of mangiferin and lupeol content in Mangifera indica pulp and peel during storage, Food chemistry 2015; 176: 91-8.
- Sethiya NK, Trivedi A, Mishra SH, Rapid validated HPTLC method for simultaneous estimation of mangiferin and scopoletin in Canscora decussate extract, Revista B D Pharmocognosia 2015; 193-198.
- Khurana RK et al.: Analytica Quality by design for developing a validated HPTLC densitometry method for estimating mangiferin in human plasma, Current Pharmaceutical Analysis 2015; 3.
- Kaliappan I et al.: LC-MS quantification of mangiferin inhydroalcoholic extract of Salacia oblonga, S. roxburghii and Polyherbal formulations, International Journal of Phytopharmacy; 2014, 4:11-15.
- Padh H, Parmar S and Patel B: Stability indicating HPTLC method for estimation of mangiferin in bulk and dosage form, International Journal of Pharmacy and Biological Sciences 2017, 7: 71-77.
- Mandlik S, Ghadge A and Ranpise N: analytical method development and validation of phytoconstituent - berberine hydrochloride by RP-HPLC method, Inventi Rapid Phamaceutical Analysis and Quality assurance 2017: 1-5.
- Wang J, Zhang Q and Cai D: Stability-Indicating Validated HPLC method for analysis of berberine hydrochloride and trimethoprim in pharmaceutical dosage form. Journal of Chemistry 2017: 1-9.
How to cite this article:
Padh H, Parmar S and Patel B and: Development and validation of q-absorbance ratio spectrophotometric method for simultaneous estimation of mangiferin and berberin HCl in bulk and synthetic mixture. Int J Pharm Sci Res 2018; 9(8): 3355-59. doi: 10.13040/IJPSR.0975-8232.9(8).3355-59.
All © 2013 are reserved by International Journal of Pharmaceutical Sciences and Research. This Journal licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.
Article Information
27
3355-3359
496
1037
English
IJPSR
H. Padh, S. Parmar * and B. Patel
Department of Pharmaceutical Sciences, Sardar Patel University, Vallabh Vidyanagar, Gujarat, India.
shraddhajparmar@gmail.com
25 November, 2017
11 February, 2018
04 March, 2018
10.13040/IJPSR.0975-8232.9(8).3355-59
01 August, 2018